Inclusion Criteria:

• * Subjects 18-65 years of age
• * Acne scars on the face
• * Able and willing to comply with all study procedures and at home care; and,
• * Able and willing to give informed consent.

Exclusion Criteria:

• * Hypersensitive to light in the near infrared wavelength region
• * On medication known to increase sensitivity to sunlight
• * Seizure disorder triggered by light
• * Takes or has taken oral isotretinoin, such as Accutane®, within the last six months
• * Use of topical over the counter or prescription retinoids such as Retinol creams, gels, Tazarotene, Tretinoin, Adapalene, within the last 30 days
• * Active acne or rosacea
• * Active localized or systemic infection, or an open wound or abscess in area being treated
• * Significant systemic inflammatory disease or illness, such as lupus, or an illness localized in area being treated
• * Common acquired nevi that are predisposed to the development of malignant melanoma
• * Current or prior herpes simplex in the target treatment area
• * Is receiving or has received gold therapy
• * Currently enrolled in an investigational drug or device trial, or has received an investigational drug or was treated with an investigational device within in the area to be treated 6 months prior to study entry
• * Facial cosmetic procedures in the target areas within previous 6 months (e.g., laser or other energy-based device treatment, microdermabrasion, injection of dermal filler)
• * Micro-needling and/or chemical peel on the target treatment area in the past 3 months
• * Injection of cosmetic neurotoxins such as botulinum toxin in the treatment areas within the previous 3 months of standard duration toxins, and 6 months for long lasting neurotoxin therapy
• * Significant uncontrolled concurrent illness, such as diabetes mellitus, hypertension, or cardiovascular disease
• * History of immunosuppression/immune deficiency disorder or currently using immunosuppressive medications
• * Planned weight loss of greater than five pounds
• * Facial hair in the treatment areas which would prevent evaluation of the outcome measures. For men, must be clean shaven in the area of treatment
• * Any condition or situation which, in the investigators opinion, may put the subject at significant risk, may confound study results or may interfere significantly with the subject's participation
• * Is pregnant or of childbearing potential and not using medically effective birth control, or has been pregnant in the last 3 months, is currently breast feeding or planning a pregnancy during the study.
• * Has had unprotected sun exposure within four weeks of treatment, including the use of tanning beds or plans for unprotected sun exposure during the course of the study,
• * Has used tanning products, such as creams, lotions and sprays within four weeks prior to treatment.
• * Coagulation disorder or currently using anti-platelet/anticoagulation medication, including use of aspirin, or fish oil supplements
• * Taking medications that alter the wound-healing response or evidence of compromised wound healing
• * Known history of keloid formation
• * Known history of medical diseases that may cause koebnerization (the appearance of disease in another location), such as vitiligo, psoriasis or lichen planus
• * History of skin cancer or suspicious lesions in treatment area
• * Subject is relocating out of the zone of the study site (ie. Moving out of state or about 50+ miles away from study area)
• * Subject has history or active melasma or other pigmentary disorders such as vitiligo.